Home » Stocks » IMMP

Immutep Limited (IMMP)

Stock Price: $3.52 USD 0.32 (10.00%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 214.68M
Revenue (ttm) 11.38M
Net Income (ttm) -9.29M
Shares Out 64.87M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.52
Previous Close $3.20
Change ($) 0.32
Change (%) 10.00%
Day's Open 3.24
Day's Range 3.24 - 3.52
Day's Volume 545,241
52-Week Range 0.95 - 7.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer an...

1 week ago - GlobeNewsWire

SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from t...

3 weeks ago - GlobeNewsWire

Investors liked the company's latest regulatory update.

1 month ago - The Motley Fool

Vericity (VERY) stock is on the rise Thursday morning despite a lack of news for the company in what could be a mix-up for investors. The post VERY Stock: Is a VERY Big Mix-Up Causing Vericity to Skyroc...

Other stocks mentioned: GME, PLL, SIGL, VERY, VRYYF, ZM, ZOOM
1 month ago - InvestorPlace

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia....

Other stocks mentioned: APRE
1 month ago - Benzinga

IMMP stock is getting a boost in Thursday trading after European regulators gave one of its cancer antibodies a key patent. The post IMMP Stock: The Big Patent News Boosting Immutep Today appeared first...

1 month ago - InvestorPlace

Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...

1 month ago - GlobeNewsWire

Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer,...

1 month ago - GlobeNewsWire

Immutep was one of the Benzinga Biotech Small Cap Conference held virtually on March 24 & 25, 2021. The information contained in this article in no way represents investment advice or opinion on the par...

1 month ago - Benzinga

Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...

Other stocks mentioned: BMY, CLVS, GSK, ITRM, NNVC, NVS
1 month ago - InvestorPlace

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Other stocks mentioned: APOP, EVFM, FSTX, PRQR
1 month ago - Benzinga

Sydney, AUSTRALIA, March 17, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...

1 month ago - GlobeNewsWire

Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1s...

Other stocks mentioned: MRK
1 month ago - Benzinga

Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...

1 month ago - GlobeNewsWire

Follows positive efficacy and safety review Follows positive efficacy and safety review

2 months ago - GlobeNewsWire

Highlights

3 months ago - GlobeNewsWire

Immutep's Collaboration and Exclusive License with GSK Remains in Place Immutep's Collaboration and Exclusive License with GSK Remains in Place

3 months ago - GlobeNewsWire

Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is ple...

4 months ago - GlobeNewsWire

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer a...

4 months ago - GlobeNewsWire

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for ...

Other stocks mentioned: GLSI, SLS
4 months ago - GuruFocus

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reported ...

Other stocks mentioned: IVBXF, JD, SBHMY, SVA
4 months ago - Seeking Alpha

Shares of IMMP stock are taking off on Thursday after the firm's China-based partner announced a new breast cancer treatment trial in 2021. The post IMMP Stock: Why Immutep Stock Is Up 225% So Far Today...

4 months ago - InvestorPlace

Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metast...

Other stocks mentioned: GLSI, THC
4 months ago - Benzinga

Shares of Immumetp Ltd., an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer.

4 months ago - Market Watch

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pl...

5 months ago - GlobeNewsWire

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is plea...

5 months ago - GlobeNewsWire

SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “...

5 months ago - GlobeNewsWire

Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ ...

5 months ago - GlobeNewsWire

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release                                                                                                                    

6 months ago - GlobeNewsWire

SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...

6 months ago - GlobeNewsWire

SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is ple...

6 months ago - GlobeNewsWire

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement...

6 months ago - GlobeNewsWire

SYDNEY, Australia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today ...

6 months ago - GlobeNewsWire

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...

6 months ago - GlobeNewsWire

SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...

6 months ago - GlobeNewsWire

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poste...

7 months ago - GlobeNewsWire

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data w...

7 months ago - GlobeNewsWire

SYDNEY, Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner...

8 months ago - GlobeNewsWire

SYDNEY, Australia, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...

8 months ago - GlobeNewsWire

SYDNEY, Australia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...

8 months ago - GlobeNewsWire

SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to ...

9 months ago - GlobeNewsWire

SYDNEY, Australia, June 29, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cance...

10 months ago - GlobeNewsWire

SYDNEY, Australia, June 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate from t...

10 months ago - GlobeNewsWire

Presented at ASCO 2020 Annual Meeting

11 months ago - GlobeNewsWire

SYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is...

11 months ago - GlobeNewsWire

SYDNEY, Australia, May 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer ...

11 months ago - GlobeNewsWire

SYDNEY, Australia, April 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cance...

1 year ago - GlobeNewsWire

SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing partner ...

1 year ago - GlobeNewsWire

SYDNEY, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed ...

1 year ago - GlobeNewsWire

SYDNEY, Australia, March 24, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatm...

1 year ago - GlobeNewsWire

About IMMP

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evalu... [Read more...]

Industry
Biotechnology
CEO
Marc Voigt
Country
Australia
Stock Exchange
NASDAQ
Ticker Symbol
IMMP
Full Company Profile

Financial Performance

In 2020, Immutep's revenue was 16.50 million, an increase of 120.31% compared to the previous year's 7.49 million. Losses were -13.47 million, -26.58% less than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Immutep stock is "Buy." The 12-month stock price forecast is 7.09, which is an increase of 101.42% from the latest price.

Price Target
$7.09
(101.42% upside)
Analyst Consensus: Buy